Skip to main content
Clinical Trials/NCT04338971
NCT04338971
Completed
Not Applicable

Ipsihand Device Use in Stroke Patients to Assess Motor Recovery of the Upper Extremity and Functional Outcomes

Neurolutions, Inc.3 sites in 1 country24 target enrollmentStarted: May 5, 2017Last updated:
ConditionsStroke
InterventionsIpsiHand Therapy

Overview

Phase
Not Applicable
Status
Completed
Sponsor
Neurolutions, Inc.
Enrollment
24
Locations
3
Primary Endpoint
Fugl-Meyer Assessment - Upper Extremity

Overview

Brief Summary

This study aims to evaluate the impact of the Neurolutions Upper Extremity Rehabilitation System, known as IpsiHand, on improving functional motor control for post-stroke patients with hemiparesis. The Neurolutions System is a brain-computer interface (BCI) comprised of a robotic orthosis, worn on the hand and wrist, and operated by the patient's brain waves which are measured by EEG electrodes. The system also utilizes a tablet interface to provide therapy instructions to the patient.

Detailed Description

Participants will complete 12 weeks of home therapy with the Neurolutions IpsiHand System. Outcomes will be based on a comparison of the patient's baseline measurements to post-therapy assessments.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 85 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • 6-months or more post stroke
  • Presentation of upper extremity hemiparesis or hemiplegia
  • Participants must english speaking
  • Demonstrate intact cognition to provide informed consent
  • Botox injections are allowed, and must continue regimen at regular intervals throughout the study

Exclusion Criteria

  • Not active in another clinical study
  • Not receiving formal therapy for the upper extremity
  • No use of other modalities or technologies to the upper extremity
  • Cognitive Impairment: Short Blessed Test Score 9 or above
  • Significant Spasticity: Modified Ashworth Scale score 3 or more at the elbow
  • Significant Hemispatial Neglect: Mesulam Cancellation Test 3 or more unilaterally
  • Insufficient Strength: Motricity Index score for shoulder abduction 18 - Any contractors of the affected upper extremity that would not allow the IpsiHand robotic exoskeleton to be worn comfortably and/or safely for device use

Arms & Interventions

IpsiHand Device

Experimental

All participants will receive treatment with the IpsiHand Device.

Intervention: IpsiHand Therapy (Device)

Outcomes

Primary Outcomes

Fugl-Meyer Assessment - Upper Extremity

Time Frame: "Fugl-Meyer Assessment - Upper Extremity" average change in points from the baseline average score and 12-week average score.

The Fugl-Meyer Assessment (FMA) is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning and joint functioning in patients with post-stroke hemiplegia. It is applied clinically and in research to determine disease severity, describe motor recovery, and to plan and assess treatment. The FMA is a score on a scale of 0 to 66 points. A lower score indicates impaired motor function in the upper extremity assessed. A higher score on the scale indicates better motor function of the upper extremity. A score of 66 would indicate there is no motor function impairment of the upper extremity.

Secondary Outcomes

  • Arm Motor Ability Test Change Points on Scale From Baseline to 12 Weeks(Change in AMAT score (points) from Baseline to 12 Weeks)

Investigators

Sponsor
Neurolutions, Inc.
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (3)

Loading locations...

Similar Trials